Firehawk® Rapamycin Target Eluting Coronary Stent System is the World’s First and Only Target Eluting Stent (TES), which is the new generation product of Shanghai MicroPort Medical (Group) Co., Ltd. following the Firebird and Firebird2 stent to treat coronary artery stenosis or occlusion disease.
- Adopted the platform of TES Technology®
- Coating exposed area is only 20% of the stent surface
- Drug in-vivo released over 90 days
- Polymer fully absorbed in 9 months
- Average Metal Coverage Rate14.0-16.1%
- The world`s lowest drug dosage stent, which gets the same validity with only 1/3 drug loadings compare to similar products